In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

Participants taking the pill saw their A1C levels, a key indicator of long-term blood sugar control, drop by 1.3 to 1.6 percent. By comparison, the placebo group saw only a 0.1 percent decline ...

Novo Nordisk's Rybelsus, a daily pill with the same properties as Ozempic, was FDA-approved for diabetes in 2019. However, its weight loss results didn't stack up to other GLP-1 drugs in studies ...

An experimental weight-loss pill helped people drop 13% of their body weight in a three-month period. The results from early clinical trials were presented by Novo Nordisk this week.

Weight loss pills are likely to be years away given the lengthy process of testing medicines. Ozempic and Wegovy maker Novo Nordisk is ahead of the pack when it comes to getting an oral weight ...

Daily pill led to 10.4% weight loss in three months compared to Wegovy 15% weight loss in a year. Amycretin combines GLP-1 with new amylin hormone approach.

Early tests showed patients using the tablet had a 16 percent weight loss. The pharmaceutical company has confirmed that they are seeking approval for their new pill form in the United States.

There’s always a lot riding on these presentations, called readouts. But this one, for Lilly’s first diabetes and weight-loss pill based on the GLP-1 hormone, was particularly fraught.

Made in the USA, a new daily oral weight-loss pill from Eli Lilly won't require cold storage and is expected to hit markets in 2026. It reportedly works as well as Ozempic.

Pfizer is facing another setback with its weight-loss pill, danuglipron. The pharmaceutical giant stopped development of the drug after liver issues affected one patient. Fox Business.

FRIDAY, April 18, 2025 (HealthDay News) — A new pill designed to help with weight loss and blood sugar control is showing promise in early studies. Eli Lilly said its experimental drug, ...